Dr. Euan Ashley - 28 May 2026 Form 4 Insider Report for DEXCOM INC (DXCM)

Reporting relationship: Director
Issuer ticker: DXCM
Reported as of: 28 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jun 2026, 17:34:32 UTC
Prior SEC filing: 28 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Jereme M. Sylvain, as Attorney-in-Fact for Dr. Euan Ashley

Key filing fact

Dr. Euan Ashley filed Form 4 for DEXCOM INC (DXCM) on 01 Jun 2026.

Key facts

This page summarizes Dr. Euan Ashley's Form 4 filing for DEXCOM INC (DXCM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jun 2026, 17:34.

Change

Previous filing in this sequence was filed on 28 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002092523 Primary reporting owner

Ashley Euan A.

Relationship: Director
Address: 6340 SEQUENCE DRIVE, SAN DIEGO
Signature: /s/ Jereme M. Sylvain, as Attorney-in-Fact for Dr. Euan Ashley
Signature date: 01 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DXCM transaction

Common Stock

Award

Transaction value
Shares: +5,565
Change %: +78%
Price: $0.000000^*
Shares after: 12,731
Date: 28 May 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

Footnote F2

Included in this number are 12,731 unvested restricted stock units, 5,565 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 7,166 of which were granted on October 24, 2025 and shall vest through October 24, 2028.